Zobrazeno 1 - 10 of 340 pro vyhledávání: '"James J. Vredenburgh"'
1
Akademický článek
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
Autor: Vinay Mathew Thomas, Poorva Bindal, James J. Vredenburgh
Publikováno v: Case Reports in Oncology, Vol 12, Iss 1, Pp 126-130 (2019)
Meningiomas are primary CNS tumors that arise from the arachnoid layer of the meninges. Genomic sequencing has revealed that NF2 mutations are the most common genetic alteration seen in meningiomas. Meningiomas although usually low grade, can sometim
Externí odkaz: https://doaj.org/article/eaf2d42b020e4f39aa028a66197f9dac
Zobrazit plný text záznamu
6
Data from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Autor: James J. Vredenburgh, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Leighann Bailey, John Sampson, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, Jennifer A. Quinn, Jennifer Marcello, James E. Herndon, David A. Reardon, Annick Desjardins
Purpose: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bc4c8b61c92c61495b258cf356c5f5
https://doi.org/10.1158/1078-0432.c.6516909.v1
Zobrazit plný text záznamu
7
Akademický článek
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
Autor: Emil Lou, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon II, April Coan, Leighann Bailey, Scott Turner, Henry S. Friedman, James J. Vredenburgh
Publikováno v: Cancer Medicine, Vol 2, Iss 2, Pp 185-195 (2013)
Abstract Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5‐day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or
Externí odkaz: https://doaj.org/article/878b6c7f1e0040d09fdb3980bb1eb49e
Zobrazit plný text záznamu
8
A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker
Autor: James J. Vredenburgh, Alla Turshudzhyan
Publikováno v: Current Oncology
Current Oncology, Vol 28, Iss 21, Pp 196-202 (2021)
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small-cell lung cancer (NSCLC) is an exceptionally rare form of lung cancer, found only in one to two percent of patients with an NSCLC diagnosis. BRAF NSCLC traditionally affects form
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d211481ac277408a35337f615f3c0ba8
https://doi.org/10.3390/curroncol28010021
Zobrazit plný text záznamu
10
Akademický článek
Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report
Autor: Katherine B. Peters, Roger McLendon, Michael A. Morse, James J. Vredenburgh
Publikováno v: Case Reports in Oncology, Vol 3, Iss 1, Pp 93-97 (2010)
Hemangiopericytoma (HPC) is a rare sarcomatous tumor arising from pericytes, a support cell found in blood vessels. These tumors can occur throughout the body, particularly in the lower extremities and retroperitoneum. In rare circumstances, HPCs can
Externí odkaz: https://doaj.org/article/8a68810a9e404e3b990b49f454b9ff9b
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje